Pilot, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety Clinical Activity of CCX282-B in Patients With Moderate to Severe Crohn's Disease

Trial Profile

Pilot, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety Clinical Activity of CCX282-B in Patients With Moderate to Severe Crohn's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2014

At a glance

  • Drugs Vercirnon (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top